Fresh analysis reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a major health publication points out that while overweight individuals can lose about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People buying these treatments should be cognizant of the potential of quick weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.
Such speed of regain implies a return to original mass within about a year and a half.
Weighing Therapies
The study, which reviewed 37 of studies involving over 9,000 of participants, compared the results of the injectable medications with older methods.
The team emphasize that individuals who shed pounds through diet and exercise generally have a less rapid creep back—around 0.1 kg a month—after stopping.
Explaining the Quick Regain
Nutrition scientists propose the way of the drugs accounts for the amplified weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Condition?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, due to the significant potential of weight regain, the therapy might need to be ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the long-term character of obesity," similar to managing conditions like hypertension.
User Accounts
Individuals who have stopped the medication explain a powerful resurgence of hunger.
"It felt as if a switch that goes on and you become extremely hungry," described a patient.
This difficulty is exacerbated if users have not developed sustainable dietary or behavioural modifications during treatment.
Widespread Use
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is higher among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are powerful agents for weight loss, they are not a magic cure and lasting health benefits likely depends on ongoing lifestyle support.
